Aerie Pharmaceuticals (Aerie Pharmaceuticals) Debt-to-Equity : -2.06 (As of Sep. 2022)

View and export this data going back to 2013. Start your Free Trial

What is Aerie Pharmaceuticals Debt-to-Equity?

Aerie Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2022 was $4.9 Mil. Aerie Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2022 was $332.1 Mil. Aerie Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Sep. 2022 was $-164.0 Mil. Aerie Pharmaceuticals's debt to equity for the quarter that ended in Sep. 2022 was -2.06.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Aerie Pharmaceuticals's Debt-to-Equity or its related term are showing as below:

AERI' s Debt-to-Equity Range Over the Past 10 Years
Min: -795.55 Med: 0.72 Max: 9.41
Current: -2.06

During the past 11 years, the highest Debt-to-Equity Ratio of Aerie Pharmaceuticals was 9.41. The lowest was -795.55. And the median was 0.72.

AERI's Debt-to-Equity is not ranked
in the Drug Manufacturers industry.
Industry Median: 0.29 vs AERI: -2.06

Aerie Pharmaceuticals Debt-to-Equity Historical Data

The historical data trend for Aerie Pharmaceuticals's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aerie Pharmaceuticals Debt-to-Equity Chart

Aerie Pharmaceuticals Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Debt-to-Equity

Get a 7-Day Free Trial

0.91

1.24

9.41

-15.04

Aerie Pharmaceuticals Quarterly Data
	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
Debt-to-Equity	Get a 7-Day Free Trial															-3.49	-15.04	-2.68	-2.39	-2.06

Competitive Comparison of Aerie Pharmaceuticals's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Aerie Pharmaceuticals's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aerie Pharmaceuticals's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Aerie Pharmaceuticals's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Aerie Pharmaceuticals's Debt-to-Equity falls into.

Aerie Pharmaceuticals Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Aerie Pharmaceuticals's Debt to Equity Ratio for the fiscal year that ended in Dec. 2021 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(4.365	+	256.278)	/	-17.333
	=	-15.04

Aerie Pharmaceuticals's Debt to Equity Ratio for the quarter that ended in Sep. 2022 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(4.873	+	332.113)	/	-163.982
	=	-2.06

Aerie Pharmaceuticals (NAS:AERI) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Aerie Pharmaceuticals Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Aerie Pharmaceuticals's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Aerie Pharmaceuticals (Aerie Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Aerie Pharmaceuticals Inc (NAS:AERI) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

4301 Emperor Boulevard, Suite 400, Durham, NC, USA, 27703

Website

https://www.aeriepharma.com

Aerie Pharmaceuticals Inc is a clinical-stage pharmaceutical company. It is focused on the discovery, development, and commercialization of therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases, and retinal diseases. Its main products are Rhopressa and Roklatan. The company mainly operates in North America.

Executives

Peter Frederick Lang	officer: Chief Financial Officer	AERIE PHARMACEUTICALS, INC., 4301 EMPEROR BLVD., SUITE 400, DURHAM NC 27703
Raj Kannan	director, officer: Chief Executive Officer	C/O CHIASMA, INC. 460 TOTTEN POND RD, SUITE 530, WALTHAM MA 02451
Jeffrey Calabrese	officer: Vice President of Finance	AERIE PHARMACEUTICALS, INC., 4301 EMPEROR BLVD., SUITE 400, DURHAM NC 27703
Kathleen Mcginley	officer: CHRO & VP, Corp Services	15279 ALTON PARKWAY SUITE 100, IRVINE CA 92618
Christopher Staten	officer: Interim CFO	AERIE PHARMACEUTICALS, INC., 4301 EMPEROR BOULEVARD, SUITE 400, DURHAM NC 27703
Casey C. Kopczynski	officer: Chief Scientific Officer	135 U.S. HIGHWAY 206, SUITE 15, BEDMINSTER NJ 07921
Peter J Mcdonnell	director	2525 DUPONT DRIVE, IRVINE CA 92612
Gerald D. Cagle	director	135 U.S. HIGHWAY 206, SUITE 15, BEDMINSTER NJ 07921
Foresite Capital Fund Ii, L.p.	10 percent owner	600 MONTGOMERY STREET, SUITE 4500, SAN FRANCISCO CA 94111
David Hollander	officer: Chief R&D Officer	C/O AERIE PHARMACEUTICALS, INC., 4301 EMPEROR BLVD., SUITE 400, DURHAM NC 27703
Richard J Rubino	officer: Chief Financial Officer
Vicente Jr Anido	director, officer: Chief Executive Officer	1621 BAYSIDE DR, CORONA DEL MAR CA 92625
Foresite Capital Management Iv, Llc	10 percent owner	900 LARKSPUR LANDING CIRCLE, SUITE 150, LARKSPUR CA 94939
Foresite Capital Fund Iv, L.p.	10 percent owner	600 MONTGOMERY STREET, SUITE 4500, SAN FRANCISCO CA 94111
Thomas A Mitro	officer: President and COO	15279 ALTON PARKWAY SUITE #100, IRVINE CA 92618